
Is BIIB (Biogen Inc.) Halal or Haram?
Biogen Inc. successfully passes all AAOIFI shariah screening criteria, making it a halal investment. The company maintains a healthy balance sheet with a debt-to-market cap ratio of 24.8% and cash reserves at 13.6%, both well below the 33% threshold. Furthermore, its interest income is negligible at just 0.89% of total revenue, easily clearing the 5% limit.
Price Chart (5D)
BIIB — Last 7 Days
| Date | Open | High | Low | Close | Volume | Change |
|---|---|---|---|---|---|---|
| 2026-05-01 | 189.28 | 190.57 | 186.14 | 187.06 | 697K | -1.17% |
| 2026-04-30 | 194.02 | 195.98 | 187.16 | 189.28 | 1.6M | -2.44% |
| 2026-04-29 | 183.12 | 195.89 | 180.18 | 194.38 | 2.5M | +6.15% |
| 2026-04-28 | 182.45 | 184.41 | 181.89 | 183.38 | 1.2M | +0.51% |
| 2026-04-27 | 183.16 | 186.15 | 179.15 | 180.67 | 1.1M | -1.36% |
| 2026-04-24 | 186.65 | 186.65 | 183.17 | 184.38 | 723K | -1.22% |
| 2026-04-23 | 189.46 | 190.32 | 187.01 | 187.88 | 816K | -0.83% |
Discussion
Sign in to join the discussion
Loading comments...
Shariah Screening Details for BIIB
Business Activity
Permissible
Biogen's core business of developing therapies for neurological conditions like multiple sclerosis and Alzheimer's disease is fully permissible under Islamic guidelines, as it focuses on life-saving healthcare.
Debt / Market Cap
24.84%
Interest Income
0.89%
Cash & Securities
13.64%
About Biogen Inc. (BIIB)
Biogen Inc. is a leading biotechnology company that discovers, develops, and delivers therapies for severe neurological and neurodegenerative diseases. Its prominent portfolio includes multiple sclerosis treatments like TECFIDERA and AVONEX, as well as SPINRAZA for spinal muscular atrophy and ADUHELM for Alzheimer's disease.
For Muslim investors, Biogen represents a fully compliant healthcare stock, achieving a Halal status across all four AAOIFI screening criteria. The company's core operations in life-saving drug manufacturing align perfectly with Islamic ethical values, while its financial structure comfortably passes all screening thresholds.
From an Islamic finance perspective, Biogen showcases strong financial discipline with a debt-to-market cap ratio of 24.8%, keeping it safely below the 33% limit. Additionally, its interest-bearing securities and cash equivalents sit at a conservative 13.6%, and interest income is minimal at 0.89%, ensuring investors are largely shielded from riba-related earnings.
While Biogen's current operations and financials are clearly halal, Muslim investors should continue to monitor its debt levels during major acquisitions or clinical trial funding phases. Staying updated on their quarterly financial ratios will ensure the stock remains compliant within AAOIFI boundaries.
CEO
Christopher A. Viehbacher
Employees
7,605
IPO Date
1991-09-17
Headquarters
Cambridge, MA, US
Website
www.biogen.comBIIB Key Financial Statistics
Revenue
$9.81B
Net Income
$1.29B
EPS (Diluted)
$8.83
Stock Price
190.60
Beta
0.16
52-Week Range
115.25-202.41
Total Debt
$6.95B
Total Equity
$18.26B
Current Ratio
2.68
BIIB Financial Health & Profitability
Profit Margins
Revenue Growth (YoY)
+1.4%
Prior year: $9.68B
Net Debt
$3.94B
Cash: $3.01B — Debt: $6.95B
R&D Spending
$1.95B
% of Revenue
19.9%
Frequently Asked Questions About BIIB
Is BIIB (Biogen Inc.) stock halal to invest in?▾
What does Biogen Inc. do?▾
What screening criteria were used for BIIB?▾
Does BIIB require income purification?▾
When was BIIB last screened?▾
Disclaimer
This shariah compliance assessment for BIIB (Biogen Inc.) is provided for informational purposes only and does not constitute financial, investment, or religious advice. Screening criteria are based on widely accepted AAOIFI standards, but individual scholars may differ in their opinions. Always consult with a qualified Islamic scholar and licensed financial advisor before making investment decisions. Past screening status does not guarantee future compliance. Last screened: 2026-04-29.